文献速递免疫规划卫生政策与健康促进

2022年ICT新冠疫苗毒理学研讨会报告:产业界、监管机构与合同研究组织视角

Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
PubMed 文献 · Vaccine · 2023-08-25

报告2022年ICT研讨会内容,从疫苗制造商、合同研究组织(CRO)和监管机构三方视角,讨论新冠疫苗非临床毒理学研究。研讨会分析了不同疫苗技术平台、全球注册申报管理、研究紧急实施与报告,以及监管审评中安全性、质量与审批压力的平衡。

要点

  • 新冠疫苗非临床毒理学研究是疫苗安全性评价的重要组成部分。
  • 临床试验前毒理学评价的范围取决于候选疫苗类型及已有支持性数据。
  • 已有数据的疫苗可并行完成全面毒理学评价以节省时间,数据有限者需先完成毒理学再进入临床。

核心结论

  • 研讨会从疫苗制造商、CRO和监管机构三方视角审视了新冠疫苗的非临床毒理学研究。
  • 临床试验前毒理学评价的范围取决于候选疫苗类型及已有支持性信息。

研究设计与样本

  • 2022年ICT研讨会报告,汇集疫苗制造商、合同研究组织(CRO)和监管机构的视角。

主要发现

  • 2020年3月全球监管机构开会考虑如何启动早期临床试验并接受滚动提交。
  • 已有数据的候选疫苗可节省时间,同时并行完成全面毒理学评价。
  • 数据有限的疫苗需在临床开发开始前获得毒理学数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Covid pandemic took the world by surprise in late 2019 and the need for rapid development of vaccines became paramount. The challenge was how to accelerate standard vaccine development times as much as possible. With knowledge of the genetic code of SARsCOV2, vaccine manufacturers throughout the world have risen to the challenge and several new vaccines were rapidly developed for emergency use. In March 2020, global Regulatory Authorities met to consider how to start early clinical trials and accept rolling submissions. Before use in clinical trials or any mass vaccination campaigns, the safety of the candidate vaccine needs to be evaluated. Non-clinical toxicology studies are required as an important part of vaccine safety evaluation. The extent of the toxicology evaluation prior to the start of clinical trials depended on several factors, including: the type of the candidate vaccine as well as already available supportive information with the candidate vaccine or similar vaccine types. For vaccine candidates with pre-existing data, this would save valuable time whilst a full toxicology evaluation was completed in parallel. For vaccines with more limited data, toxicology data was required before clinical development could start. This workshop examined the nonclinical toxicology studies for new Covid vaccines from the perspectives of: Vaccine manufacturers with different vaccine technologies, managing global regulatory submissions/responses; CROs, managing the urgency of conducting and reporting studies and supporting new players in the vaccine world; and Regulatory Authorities, in supporting the review process, juggling the need for safety and quality with mounting pressure to approve vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gould S, Wrzesinski C, Stebbings R, et al. Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives. Vaccine. 2023. PMID: 37633751. doi:10.1016/j.vaccine.2023.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。